bufanolides - CISMeF

Preferred Label : bufanolides;

MeSH definition : Cyclopentanophenanthrenes with a 6-membered lactone ring attached at the 17-position and SUGARS attached at the 3-position. They are found in BUFONIDAE and often possess cardiotonic properties.;

MeSH hyponym : bufadienolides;

MeSH annotation : includes bufenolides, bufatrienolides;

Wikipedia link : https://en.wikipedia.org/wiki/Bufanolides;

Is substance : O;

Details

Origin ID

D002018;

UMLS CUI

C0006350;

Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Pharmacological action(s)
- cardiotonic agents [MeSH Descriptor]
Record concept(s)
- bufadienolides [MeSH concept]
- bufanolides [MeSH concept]
Related MeSH Supplementary Concept(s)
- 12-oxo-16beta-hydroxy-3-epi-resibufogenin [MeSH Supplementary Concept]
- 12-oxohellebrigenin-3-O-4,6-dideoxyhexopyranoside [MeSH Supplementary Concept]
- 12beta,15-epoxy-3-epi-bufalin-14,15-ene [MeSH Supplementary Concept]
- 12beta-hydroxyscillirosidin [MeSH Supplementary Concept]
- 14-hydroxy-3-oxo-1,4,20,22-bufatetraenolide [MeSH Supplementary Concept]
- 14beta-hydroxy-3beta-(beta-D-glucopyranosyloxy)-5alpha-bufa-20,22-dienolide [MeSH Supplementary Concept]
- 14beta-hydroxybufa-3,5,20,22-tetraenolide [MeSH Supplementary Concept]
- 19-norbufadienolide [MeSH Supplementary Concept]
- 20,21-epoxyresibufogenin-3-acetate [MeSH Supplementary Concept]
- 20,21-epoxyresibufogenin-3-formate [MeSH Supplementary Concept]
- 22,23-dihydrobufalin [MeSH Supplementary Concept]
- 3-acetyl 15beta-hydroxyl bufotalin [MeSH Supplementary Concept]
- 3beta,16beta-dihydroxy-5beta-bufa-20,22-dienolide [MeSH Supplementary Concept]
- 3beta-(O-beta-D-glucopyranosyl)-14beta-hydroxy-5alpha,19-oxobufa-20,22-dienolid [MeSH Supplementary Concept]
- 3beta-(beta-D-glucopyranosyloxy)-5alpha,14beta-bufa-20,22-dienolide [MeSH Supplementary Concept]
- 4beta,8beta,11alpha,14beta-tetrahydroxybufa-5,20,22-trienolide-12-one, 2alpha,3beta-O-4,6-dideoxy-L-glucose [MeSH Supplementary Concept]
- 6beta-acetoxy-3beta,8beta,14beta-trihydroxy-12-oxobufa-4,20,22-trienolide [MeSH Supplementary Concept]
- 6beta-hydroxy-5beta-bufa-20,22-dienolide-3beta-O-beta-D-galactoside [MeSH Supplementary Concept]
- 9-oxocinobufotalin 3-adipoylarginine ester [MeSH Supplementary Concept]
- BF211 compound [MeSH Supplementary Concept]
- acrihellin [MeSH Supplementary Concept]
- arenobufagin [MeSH Supplementary Concept]
- argentinogen [MeSH Supplementary Concept]
- bryophyllin A [MeSH Supplementary Concept]
- bryophyllin B [MeSH Supplementary Concept]
- bryophyllin C [MeSH Supplementary Concept]
- bryotoxin A [MeSH Supplementary Concept]
- bryotoxin B [MeSH Supplementary Concept]
- bufadienolactam [MeSH Supplementary Concept]
- bufadienolide [MeSH Supplementary Concept]
- bufalin [MeSH Supplementary Concept]
- bufalin 3beta-acrylic ester [MeSH Supplementary Concept]
- bufarenogin [MeSH Supplementary Concept]
- bufogargarizin A [MeSH Supplementary Concept]
- bufogargarizin B [MeSH Supplementary Concept]
- bufogargarizin C [MeSH Supplementary Concept]
- bufogenin [MeSH Supplementary Concept]
- bufospirostenin A [MeSH Supplementary Concept]
- bufotalin [MeSH Supplementary Concept]
- bufotalin 3-pimeloylarginine ester [MeSH Supplementary Concept]
- bufotalin 3-succinoylarginine ester [MeSH Supplementary Concept]
- bufotoxin [MeSH Supplementary Concept]
- chan su [MeSH Supplementary Concept]
- cinobufagin [MeSH Supplementary Concept]
- cinobufotalin [MeSH Supplementary Concept]
- cinobufotalin 3-nonanedioylarginine ester [MeSH Supplementary Concept]
- cotyledoside [MeSH Supplementary Concept]
- daigremontianin [MeSH Supplementary Concept]
- desacetylcinobufagin [MeSH Supplementary Concept]
- gamabufotalin [MeSH Supplementary Concept]
- hellebrigenin [MeSH Supplementary Concept]
- hellebrigenin-3-O-6'-deoxyglucopyranoside [MeSH Supplementary Concept]
- hellebrigenin-3-O-fucopyranoside [MeSH Supplementary Concept]
- hellebrin [MeSH Supplementary Concept]
- marinobufagenin [MeSH Supplementary Concept]
- marinoic acid [MeSH Supplementary Concept]
- marinosin [MeSH Supplementary Concept]
- methyl daigremonate [MeSH Supplementary Concept]
- physodine A [MeSH Supplementary Concept]
- poaefusarin [MeSH Supplementary Concept]
- riparianin [MeSH Supplementary Concept]
- rubellin [MeSH Supplementary Concept]
- scillaren A [MeSH Supplementary Concept]
- scillarenin [MeSH Supplementary Concept]
- scillicyanoside [MeSH Supplementary Concept]
- scillicyanosidin [MeSH Supplementary Concept]
- scilliroside [MeSH Supplementary Concept]
- secobufalinamide [MeSH Supplementary Concept]
- telocinobufagin [MeSH Supplementary Concept]
- tigencaoside A [MeSH Supplementary Concept]
- tigencaoside B [MeSH Supplementary Concept]
- tyledoside D [MeSH Supplementary Concept]
- urginin [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients